AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04030325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simultaneous Personalized Feedback Intervention Delivery
Description: Simultaneous PFI delivery after baseline survey
Study NCT04030325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Boosters
Description: Text message boosters on PFI content during week of high risk drinking events
Study NCT02093390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 tablets
Study NCT02093390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole tablets
Study NCT02093390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin tablets
Study NCT02193711 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical Arthritis Cream
Study NCT02193711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Arthritis Cream
Study NCT00006305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions
Description: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions
Study NCT00006305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass
Description: Coronary Artery Bypass
Study NCT00006305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biguanides, thiazolidinediones
Description: Biguanides, thiazolidinediones
Study NCT00006305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, sulfonylurea
Description: Insulin, sulfonylurea
Study NCT00006305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
Description: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
Study NCT00981825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Fluoride
Description: Brush whole mouth twice daily for 7 days
Study NCT00305864 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo radiotherapy
Study NCT00305864 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo radiotherapy
Study NCT00305864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motexafin Gadolinium
Description: Given IV
Study NCT00305864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motexafin Gadolinium
Description: Given IV
Study NCT00305864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given orally
Study NCT00305864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given orally
Study NCT02666963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 901 Capsules, 10 or 40 mg
Study NCT02666963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01700673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered days 1-5 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
Study NCT01700673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Sargramostim will be administered days 1-10 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
Study NCT03881059 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986165 Placebo
Description: Participants will receive BMS-986165 matching placebo QD
Study NCT01920659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Training (HIT)
Description: 6 weeks of HIT, 3 times a week (3-5 1min on/off)
Study NCT01920659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REHIT
Description: 6 weeks 3 x week (20sec intervals)
Study NCT01413074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis treatment
Description: PD treatment
Study NCT01413074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis treatment
Description: HD treatment
Study NCT04375501 — intervention group
Intervention type: OTHER
Intervention: Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail
Description: If fit for anaesthesia patients may undergo relevant procedure for fractured neck of femur as per NICE guidelines within limitations of resources as defined by BOAST
Study NCT02735356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Applied topically
Study NCT01199822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Cohort 1 10 milligrams/kilogram (mg/kg) intravenously (IV) administered on Days 1 and 8, every 3 weeks; Cohort 2 20 mg/kg IV administered every 2 weeks; Cohort 3 15 mg/kg IV administered on Days 1 and 8, every 3 weeks
Study NCT03368404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBL-102 eye drops
Description: CBL-102 eye drops, 3 to 6 times per day for 3 months
Study NCT03368404 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vismed Multi eye drops
Description: Vismed Multi eye drops, 3 to 6 times per day for 3 months
Study NCT04653623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High tibial osteotomy
Description: Treatment option for medial compartment osteoarthritis of knee
Study NCT04653623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High tibial osteotomy
Description: Treatment option for medial compartment osteoarthritis of knee
Study NCT04653623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation
Study NCT03595865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafluprostin
Description: Both patients in PACG and POAG groups will dose 1 time daily in each eye for 6months. Each eye will be preformed tafluprostin 0.0015% at 9 PM.
Study NCT02732327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ-AVI
Description: Ceftazidime-Avibactam (2 g ceftazidime and 0.5 g avibactam)
Study NCT02732327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 15 mg/kg
Study NCT02732327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 15 mg/kg
Study NCT02732327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg
Study NCT02732327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600 mg
Study NCT02732327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime
Description: 2 g
Study NCT02732327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 1 g
Study NCT02732327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/tazobactam
Description: 4.5 g
Study NCT04020081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga breathing exercises and Meditation
Description: 8 Breathing exercises.The first set of 6 exercises is of the Upper Lobe breathing (Upper and Middle Lobe of the Lungs) while 7th exercise is abdominal breathing,8th exercise is yogic breathing.~6-steps Nirmal Dhyan (meditation).Step 1: Breath awareness,Step 2: Body awareness,Step 3: Thought awareness,Step 4: Refreshing awareness,Step 5: Gap awareness,Step 6: Expanding awareness.
Study NCT00204477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soy milk
Description: Each drink contained soy protein, fat, and carbohydrates calcium and phosphorous to give a total energy of 177.8 kcal. Subjects took two drinks per day.
Study NCT00204477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cow's milk
Description: Each drink contained casein, fat, carbohydrates, calcium and phosphorous to give a total energy of 178.6 kcal. Subjects took two drinks per day.
Study NCT05353634 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Effects of mNGS on infected patients
Description: The impact of mNGS on infected patients, including diagnostic value, drug selection, treatment prognosis, economic burden, etc.
Study NCT04621643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital cognitive behavioral therapy (dCBT-I)
Description: dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices
Study NCT04621643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital patient education about insomnia (PE)
Description: Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
Study NCT01430624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPRS
Description: Video including information psychoeducation and modeling of adaptive behavioral coping strategies for use post-assault. Shown at time of post assault medical exam.
Study NCT01430624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PIRI
Description: Video containing pleasant imagery and relaxation instruction information. Shown at time of post assault medical exam.
Study NCT01761305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypercorrective night-time brace
Description: Hypercorrective night-time brace worn 8 hours per night. Patients are encouraged to also continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
Study NCT01761305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scoliosis specific exercises.
Description: The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. Goals are directed towards active self-correction and postural control, spinal stability, aerobic functioning and development of a positive body image. Additional postural specific exercises including self-mediated hyper-corrective exercises are to be performed with moderate intensity at least for 30 minutes at least 2-3 times per week. Other physical activities to fulfill the general recommended quota of more than 60 minutes moderate intensity physical activity per day are recommended. Reinforcement of the intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
Study NCT01761305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-mediated physical activity.
Description: Instructions for self-mediated physical activity will be delivered during a 1 hour session. Patients are encouraged to perform self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
Study NCT03217019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guidewire-assist
Description: catheter insertion with guidewire-assist(catheter over guidewire)
Study NCT03217019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct
Description: catheter insertion without guidewire assist(catheter over needle)
Study NCT02320227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miami w/o frag Personal lubricant
Study NCT02851979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory stimulations
Description: Odors are disseminated using a portable fragrance device, a prototype developed by a research unit, CNRS UMR5292. The device is outside the incubator, the only part inside is a disposable Teflon tube. The odor flux stimulates distally the NBs' nostrils. Odoriferous compounds are placed in glass tubes. This allows the olfactometer to deliver three distinct odors (to avoid habituation) in a random scheme: spearmint odor, vanilla odor, and grapefruit odor (chemicals registered by Chemical Abstracts Service), while controlling for intensity (amount of compound), duration, and odor sequence. For the vehicle period, the glass tubes remain empty.~Stimulations occur every 5 minutes, for 5 seconds, they are mixed in medical gas to avoid infection. There are three 24-hour periods, and two 24-hour wash out periods, followed by a maximum of 3 days of surveillance.
Study NCT05270915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family supportive care in EOLC
Description: The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
Study NCT05270915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family supportive care in EOLC
Description: The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
Study NCT01881087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Levobupivacaine 0.75%
Description: Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.
Study NCT01881087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Levobupivacaine 0.75%
Description: Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.
Study NCT00236275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoro-L-thymidine-(18F)
Description: Fluoro-L-thymidine-(18F)
Study NCT03813134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Description: Primary PCI or early/immediate PCI for NSTEMI will be undertaken according to recommended Guideline standards of care. This will include appropriate pre-loading with dual anti-platelet therapy, a preferred radial approach, intra-procedural anti-coagulation (with measure of ACT if considered appropriate every 30 minutes) and the use of drug eluting stents. Treatment will be delivered essentially to the culprit vessel only. A successful procedure will be one considered to have achieved TIMI 2-3 flow and residual stenosis \< 50%. PCI failure will not be an exclusion itself from the trial.
Study NCT03813134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: Primary PCI or early/immediate PCI for NSTEMI will be undertaken according to recommended Guideline standards of care. This will include appropriate pre-loading with dual anti-platelet therapy, a preferred radial approach, intra-procedural anti-coagulation (with measure of ACT if considered appropriate every 30 minutes) and the use of drug eluting stents. Treatment will be delivered essentially to the culprit vessel only. A successful procedure will be one considered to have achieved TIMI 2-3 flow and residual stenosis \< 50%. PCI failure will not be an exclusion itself from the trial.
Study NCT03813134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Support
Description: Use of pharmacological agents (Norepinephrine, Dobutamine, Levosimendan) according to ESC Guidelines to maintain mean arterial pressure >75 mmHg in accordance with recognised standards of care. Changes in pharmacotherapy will NOT be regarded as escalation therapy. However the number of and dose of inotropes will be documented in the CRF.
Study NCT03813134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Support
Description: Use of pharmacological agents (Norepinephrine, Dobutamine, Levosimendan) according to ESC Guidelines to maintain mean arterial pressure >75 mmHg in accordance with recognised standards of care. Changes in pharmacotherapy will NOT be regarded as escalation therapy. However the number of and dose of inotropes will be documented in the CRF.
Study NCT03813134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VA-ECMO
Description: Following PCI of the culprit lesion, patients will have ECMO initiated as soon as echocardiography (to exclude mechanical causes) has been completed, once they have been assessed as having failed to improve (with the aim to start ECMO as early as possible from 30 mins after completed P-PCI procedure ad fully established within 6 hours after randomisation).~Peripheral Veno-arterial ECMO will be employed with a flow rate according to individual patient needs. Other methods of LV unloading, distal limb perfusion, maintenance of ejection/aortic valve opening and anti-coagulation will be instituted as per sites' usual care.~A minimum 24 hours be allocated to the randomised therapy in order that strategy failure is demonstrated but this will be at the physicians' discretion.
Study NCT02818621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group Dex (dexmedetomidine)
Description: 1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
Study NCT02818621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group Dex (dexmedetomidine)
Description: 1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
Study NCT01420016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prioritized Clinical Decision Support
Description: Eighteen primary care clinics were blocked on size and on patient characteristics. Each clinic was randomly assigned to one of 2 study arms. All consenting PCPs were allocated to the study arm that their clinic was assigned to and the estimated 400 eligible adults with 10-year CVR >= 10% under the care of each consenting physician were allocated to the same treatment arm as their PCP.
Study NCT00190372 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Controlled diet
Description: Controlled diet
Study NCT00190372 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-hypnotic relaxation
Description: Self-hypnotic relaxation
Study NCT02832141 — intervention group
Intervention type: PROCEDURE
Intervention: Mobilization anterior
Description: Participant in prone position. Central thoracic mobilization from posterior-to-anterior.
Study NCT02832141 — intervention group
Intervention type: PROCEDURE
Intervention: Mobilization posterior
Description: Participant in sitting position. Central thoracic mobilization from anteriors-to-posterior.
Study NCT03003000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen
Study NCT03003000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Study NCT03003000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Study NCT03003000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01785849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
Study NCT01785849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously (IV) three times per week.